BlinkLab has completed onboarding all clinical sites for its pivotal FDA autism trial, enrolled the first participant, and launched a nationwide autism screening program in Morocco. A recent A$17.7 million capital raise will fund further trials and expansion into ADHD diagnostics.
- Completed onboarding of 10 US clinical sites for FDA autism trial
- First participant enrolled in pivotal FDA 510(k) validation study
- Launched Morocco’s government-led nationwide autism screening
- Strengthened US scientific influence via publication and partnerships
- Raised A$17.7 million to fund FDA trial completion and ADHD program
Pivotal FDA Autism Trial Moves from Setup to Execution
BlinkLab Limited (ASX:BB1) marked a crucial milestone in its regulatory journey by completing the onboarding of all 10 leading U.S. clinical sites for its FDA 510(k) pivotal autism diagnostic trial. This network, now fully operational, spans premier institutions including Drexel University and the University of Arkansas, solidifying BlinkLab’s foothold in the U.S. clinical landscape. The company enrolled and completed testing of the first participant in March, initiating the validation phase designed to confirm the usability of its smartphone-based diagnostic platform in real-world clinical settings.
This trial aims to recruit approximately 528 children and is aligned with FDA protocols to generate registrational-grade evidence. BlinkLab’s prior pilot study involving 485 participants demonstrated diagnostic sensitivity and specificity above 83%, comfortably exceeding FDA’s minimum thresholds of 65%. With recruitment expected to conclude within eight months, the company targets FDA submission by the end of 2026, a pivotal inflection point for regulatory approval and commercialisation. The clinical network not only supports regulatory goals but also fosters relationships with key opinion leaders critical for post-clearance adoption and reimbursement strategies. This progress builds on the recent finalised clinical network onboarding and the first participant enrolment in FDA trial.
Morocco’s Nationwide Autism Screening Program Breaks New Ground
In a world first for digital autism diagnostics, BlinkLab’s Dx1 platform has been selected for Morocco’s government-led, nationwide autism screening initiative. This program, funded by the Moroccan government, targets early screening starting at 18 months across a population where over 400,000 individuals are affected by autism. The deployment spans a broad network of primary care and specialist centres, demonstrating BlinkLab’s ability to scale its AI-powered platform across diverse and decentralized healthcare settings.
The Moroccan initiative validates the platform’s design philosophy prioritising scalability, usability, and integration within complex healthcare systems. It also promises to generate one of the largest standardised autism screening datasets globally, enhancing BlinkLab’s data assets and supporting ongoing model refinement. This deployment positions BlinkLab as a pioneer in population-scale neurodevelopmental screening and sets a potential template for similar government-led programs internationally. The significance of this rollout was highlighted in the company’s recent Morocco national screening program announcement.
Expanding Scientific Credibility and Clinical Influence in the U.S.
BlinkLab has bolstered its scientific standing through a peer-reviewed publication in Autism Research, validating its neurometric approach to capturing sensorimotor signatures of autism via smartphone technology. This independent validation is a critical step toward regulatory acceptance and clinical adoption. Complementing this, a strategic partnership with the SHANK2 Autism Foundation integrates BlinkLab into precision neurodevelopmental medicine, enabling validation in genetically defined patient cohorts that could accelerate biomarker development.
The company’s participation in the Simons Foundation Autism Research Initiative (SFARI) further cements its role within a leading global autism research network. These engagements collectively enhance BlinkLab’s influence among clinicians and researchers, underpinning post-clearance adoption and reimbursement pathways in the U.S. market.
Capital Raise Fuels Next Growth Phase Including ADHD Expansion
Following the quarter, BlinkLab completed an oversubscribed A$17.7 million placement to institutional and sophisticated investors. This capital injection will accelerate completion of the FDA autism trial, support regulatory efforts in Europe, and fund the launch of a second clinical program targeting ADHD diagnostics. The raise underscores investor confidence in BlinkLab’s strategy and positions the company to advance multiple clinical programs simultaneously as it approaches commercialisation.
Financially, the company reported net cash used in operations of A$1.036 million for the quarter, with a cash balance of A$4.319 million at quarter-end, excluding the post-quarter capital raise. Operational expenditure focused on research and development for the FDA trial and European ADHD study, alongside corporate costs.
Bottom Line?
BlinkLab’s clinical and commercial milestones set the stage for regulatory submissions and broader market expansion, but trial outcomes and adoption in new markets remain key uncertainties.
Questions in the middle?
- Will BlinkLab’s FDA pivotal trial meet its recruitment and performance targets to enable timely submission?
- How will the Morocco screening program’s real-world data influence BlinkLab’s platform validation and adoption globally?
- Can BlinkLab’s expansion into ADHD diagnostics replicate its autism program’s clinical and regulatory progress?